Table 2.

Overview of clinical and paraclinical characteristics of antibody-positive participants

Participant No. Age/Gender	Initial Diagnosis ICD-10 31	Duration of Untreated Psychosis (Days)	Symptoms	Antibody	Seizure	CSF	Initial EEG	MRI
1. 28, F	Substance-induced psychosis (cannabis)	7	Acute confusion, headaches, hallucinations, agitation, catatonia, encephalopathy with reduction in level of consciousness 8 days after psychosis onset	NMDAR	Yes	WCC 50, Prot 360, NMDAR+	Normal	Normal
2. 16, F	Acute and transient psychotic disorder	5	Agitation, confusion, seizures, encephalopathy with seizures 9 days after onset of first symptoms	NMDAR	Yes	WCC 15, Prot 370, OCB+, NMDAR+	Fast background, right temporal slow	Normal
3. 13, M	Schizophreniform disorder	70	Irritable, confusion, labile mood, hallucinations	NMDAR	No	WCC 1, Prot 160, OCB+, NMDA low+	ND	Normal
4. 33, M	Bipolar affective disorder	2	Suicidal thoughts, delusional thoughts, hallucinations, depressed mood	NMDAR	No	WCC 35, Prot 450, OCB–, NMDA–	Normal	Normal
5. 16, M	First episode of psychosis	2	Bizarre behaviour, thought disorder	VGKC	No	WCC 2, Prot 340, OCB–, NMDA–	Diffuse slowing of background	Normal
6. 23, M	First episode of psychosis	7	Mania, psychosis	Unknown	No	ND	Normal	ND, Head computed tomography scan normal

CSF, cerebrospinal fluid; EEG, electroencephalogram; F, female; M, male; MRI, magnetic resonance imaging; ND, not done; NMDAR, N-methyl-D-aspartate receptor antibody; OCB, oligoclonal bands; Prot, protein; VGKC, voltage-gated potassium channel antibody; WCC, white cell count.